Unraveling Tempus AI’s Intriguing Options Activity: What Investors Should Know
Tempus AI, the Chicago-based artificial intelligence company specializing in precision medicine, has recently exhibited unusual options trading activity that has Wall Street buzzing. Over the past two weeks, options volume for the genomic analysis firm surged to 300% above average levels, with notable accumulation of call options expiring in January 2025. Market analysts suggest this could signal either bullish investor confidence or strategic positioning ahead of potential catalysts.
Breaking Down the Unusual Options Flow
Between June 10-24, Tempus AI (NASDAQ: TEM) saw approximately 12,000 call options traded compared to just 3,000 puts—a 4:1 ratio that stands out in the healthcare technology sector. The most active contracts were the $40 strike calls for January 2025, with open interest ballooning from 500 to over 4,200 contracts during this period. This represents a $16.8 million bullish bet at current premiums.
“When you see this kind of concentrated activity in longer-dated options, it typically indicates sophisticated investors positioning for a major move,” explains Michael Chen, derivatives strategist at Bernstein Capital. “The January 2025 expiration suggests they’re anticipating significant developments within the next 12-18 months.”
Key data points from the options surge:
- Total options volume reached 15,000 contracts vs. 30-day average of 5,000
- Call options accounted for 80% of total volume (sector average: 55%)
- Implied volatility jumped from 45% to 62% for front-month contracts
Potential Catalysts Behind the Activity
Several factors could be driving this unusual trading pattern. Tempus AI recently announced a partnership with Mayo Clinic to integrate its AI diagnostic tools, and industry sources suggest the company may be nearing FDA clearance for its liquid biopsy platform. The firm is also scheduled to present at the Morgan Stanley Healthcare Conference on September 9.
Dr. Sarah Williamson, biotech analyst at Kepler Investments, notes: “Tempus sits at the intersection of two explosive growth areas—AI and personalized medicine. Their proprietary database of over 7 million clinical cases gives them a unique advantage, and investors might be anticipating monetization of that asset.”
The company’s first-quarter earnings showed:
- Revenue growth of 58% year-over-year to $42.1 million
- Clinical test volume up 73%
- Cash position of $290 million with burn rate slowing to $18M/quarter
Bullish vs. Bearish Interpretations
While the options activity appears overwhelmingly bullish on surface, some analysts urge caution. The $40 strike represents a 120% premium to Tempus’s current $18.20 share price—an extremely aggressive bet that could simply reflect hedging strategies rather than outright optimism.
“We’ve seen this movie before with high-growth healthcare tech names,” warns David Park, managing director at Crestview Advisors. “The options market might be overestimating how quickly Tempus can scale its reimbursement pipeline. Medicare coverage decisions don’t move at Silicon Valley speed.”
Key risks investors should consider:
- Regulatory hurdles for AI-based diagnostics
- Intense competition from Guardant Health and Exact Sciences
- High R&D spend (42% of revenue) pressuring margins
Historical Context and Sector Comparisons
Similar options activity preceded major moves in other AI-healthcare crossover stocks. Exact Sciences saw call volume spike six months before its 2019 FDA approval, while Guardant Health’s options surged before its 2020 liquid biopsy coverage decision. However, not all such signals prove accurate—Illumina’s 2021 options boom preceded a 40% decline.
The healthcare AI sector currently trades at:
- 8.2x forward sales (Tempus at 6.9x)
- 32% premium to broader biotech indices
- 90-day correlation of 0.82 with big tech AI players
What Investors Should Watch Next
Market participants will closely monitor three upcoming events that could validate or contradict the options market’s optimism:
- Q2 earnings report (expected August 12)
- Potential FDA submission for Tempus’s xT assay
- Any partnership announcements with pharmaceutical companies
The unusually high open interest in January 2025 options creates a potential “gamma squeeze” scenario if the stock approaches $40, which could amplify moves in either direction. Market makers currently delta-hedging these positions may need to buy shares aggressively if Tempus’s stock gains momentum.
Expert Recommendations for Navigating the Volatility
For investors considering positions in Tempus AI, financial advisors suggest several approaches:
- Long-term holders: Consider selling covered calls to capitalize on elevated premiums
- Speculative traders: Vertical spreads may limit risk on aggressive bets
- Cautious investors: Wait for post-earnings implied volatility contraction
As Chen summarizes: “Tempus represents either a transformational opportunity or classic hype cycle—the options market is clearly pricing in the former. Investors need to decide which narrative they believe and position accordingly.”
The coming months will test whether this unusual options activity foreshadows a breakthrough moment for AI in healthcare or serves as another cautionary tale about overheated speculation in cutting-edge biotech. One thing is certain—Tempus AI has captured Wall Street’s attention, and its journey will provide valuable insights into the maturation of precision medicine technologies.
For investors seeking to stay ahead of developments, subscribing to Tempus AI’s investor relations updates and monitoring SEC Form 4 filings for insider activity could provide early signals of changing momentum.
See more Business Focus Insider Team
